A cell-based small molecule screening method for identifying inhibitors of epithelial-mesenchymal transition in carcinoma

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Chua, Kian Ngiap ^a   Sim, Wen Jing ^b   Racine, Victor ^b   Lee, Shi Yun ^c   Goh, Boon Cher ^a,d   Thiery, Jean Paul ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^c Agency for Science   (Singapore)

^d NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEINS AND BINDING PROTEINS; GEFITINIB; GROWTH FACTOR; HUMAN GROWTH HORMONE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN INHIBITOR; SOMATOMEDIN C; STEROID RECEPTOR COACTIVATOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; SCATTER FACTOR;

ARTICLE; BLADDER TUMOR; CANCER STAGING; CARCINOMA; CELL ASSAY; CELL GROWTH; CELL MIGRATION; CONTROLLED STUDY; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; PROTEIN ANALYSIS; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR CELL; BIOASSAY; CELL COUNT; DRUG EFFECT; DRUG SCREENING; HUMAN; IC 50; IMAGE PROCESSING; METHODOLOGY; MOLECULAR LIBRARY; PATHOLOGY; REPRODUCIBILITY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BIOLOGICAL ASSAY; CARCINOMA; CELL COUNT; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; EPIDERMAL GROWTH FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; HEPATOCYTE GROWTH FACTOR; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INHIBITORY CONCENTRATION 50; INSULIN-LIKE GROWTH FACTOR I; REPRODUCIBILITY OF RESULTS; SMALL MOLECULE LIBRARIES;

EID: 84863247475     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033183     Document Type: Article

References (37)

1. Lee JM, Dedhar S, Kalluri R, Thompson EW, (2006) The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172: 973-981.
2. Reese DE, Mikawa T, Bader DM, (2002) Development of the coronary vessel system. Circ Res 91: 761-768.
3. Thiery JP, (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454.
4. Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, et al. (2001) Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A 98: 10356-10361.
5. Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, et al. (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13: 58-68.
6. Bidard FC, Vincent-Salomon A, Gomme S, Nos C, de Rycke Y, et al. (2008) Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. Clin Cancer Res 14: 3306-3311.
7. Chua KN, Ma J, Thiery JP, (2007) Targeted therapies in control of EMT in carcinoma and fibrosis. Drug Discov Today Dis Mech 4: 261-267.
8. Moustakas A, Heldin CH, (2007) Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 98: 1512-1520.
9. Thiery JP, Sleeman JP, (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7: 131-142.
10. Lemmon MA, Schlessinger J, (2010) Cell signaling by receptor tyrosine kinases. Cell 141: 1117-1134.
11. Schlessinger J, (2000) Cell signaling by receptor tyrosine kinases. Cell 103: 211-225.
12. Larue L, Bellacosa A, (2005) Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene 24: 7443-7454.
13. Barr S, Thomson S, Buck E, Russo S, Petti F, et al. (2008) Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clin Exp Metastasis 25: 685-693.
14. Ponzo MG, Lesurf R, Petkiewicz S, O'Malley FP, Pinnaduwage D, et al. (2009) Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A 106: 12903-12908.
15. Arora A, Scholar EM, (2005) Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315: 971-979.
16. Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, et al. (2008) Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 111: 1039-1043.
17. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957.
18. Chua KN, Poon KL, Lim J, Sim WJ, Huang RY, et al. (2011) Target cell movement in tumor and cardiovascular diseases based on the epithelial-mesenchymal transition concept. Adv Drug Deliv Rev 63: 558-567.
19. Shinto O, Yashiro M, Kawajiri H, Shimizu K, Shimizu T, et al. (2010) Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells. Br J Cancer 102: 844-851.
20. Inglese J, Shamu CE, Guy RK, (2007) Reporting data from high-throughput screening of small-molecule libraries. Nat Chem Biol 3: 438-441.
21. Bellusci S, Moens G, Thiery JP, Jouanneau J, (1994) A scatter factor-like factor is produced by a metastatic variant of a rat bladder carcinoma cell line. J Cell Sci 107 (Pt 5): 1277-1287.
22. Rodier JM, Valles AM, Denoyelle M, Thiery JP, Boyer B, (1995) pp60c-src is a positive regulator of growth factor-induced cell scattering in a rat bladder carcinoma cell line. J Cell Biol 131: 761-773.
23. Moriya C, Jinnin M, Yamane K, Maruo K, Muchemwa FC, et al. (2011) Expression of matrix metalloproteinase-13 is controlled by IL-13 via PI3K/Akt3 and PKC-delta in normal human dermal fibroblasts. J Invest Dermatol 131: 655-661.
24. Grotegut S, von Schweinitz D, Christofori G, Lehembre F, (2006) Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail. EMBO J 25: 3534-3545.
25. Padua D, Massague J, (2009) Roles of TGFbeta in metastasis. Cell Res 19: 89-102.
26. Yeatman TJ, (2004) A renaissance for SRC. Nat Rev Cancer 4: 470-480.
27. Beucher S, Meyer F, (1993) The morphological approach to segmentation: the watershed transformation. In: Dougherty ER, editors. Mathematical Morphology in Image Processing New York Marcel Dekker Inc pp. 433-481.
28. Starck JL, Murtagh F, Bijaoui A, (1998) Image Processing and Data Analysis: The Multiscale Approach. Cambridge Cambridge University Press.
29. Chen HC, (2005) Boyden chamber assay. Methods Mol Biol 294: 15-22.
30. Liang CC, Park AY, Guan JL, (2007) In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2: 329-333.
31. Collins CS, Hong J, Sapinoso L, Zhou Y, Liu Z, et al. (2006) A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. Proc Natl Acad Sci U S A 103: 3775-3780.
32. Yarrow JC, Totsukawa G, Charras GT, Mitchison TJ, (2005) Screening for cell migration inhibitors via automated microscopy reveals a Rho-kinase inhibitor. Chem Biol 12: 385-395.
33. Bamborough P, Drewry D, Harper G, Smith GK, Schneider K, (2008) Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. J Med Chem 51: 7898-7914.
34. Yang AD, Camp ER, Fan F, Shen L, Gray MJ, et al. (2006) Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res 66: 46-51.
35. Li Y, Yang X, Su LJ, Flaig TW, (2010) VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder cancer cells. Oncol Rep 24: 1019-1028.
36. Chou TC, (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70: 440-446.
37. Singh A, Settleman J, (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29: 4741-4751.